Stock Analysis, Dividends, Split History

QVCA / Liberty Interactive Corp. Series A QVC Group financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)12,038.37
Enterprise Value ($M)19,190.37
Book Value ($M)5,687.00
Book Value / Share13.19
Price / Book2.12
NCAV ($M)-8,558.00
NCAV / Share-19.86
Price / NCAV-1.41
Share Statistics
Common Shares Outstanding 29,203,895
Common Shares Outstanding3 4,455,308
Common Shares Outstanding4 81,687,188
Common Shares Outstanding2 448,261,047
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.13
Return on Assets (ROA)0.12
Return on Equity (ROE)0.37
Balance Sheet (mrq) ($M)
Quick Ratio0.57
Current Ratio1.00
Income Statement (mra) ($M)
Other Sales Revenue Net0.00
Sales Revenue Net10,404,000,000.00
Sales Revenue Goods Net10,404,000,000.00
Sales Revenue Services Net0.00
Operating Income1,043.00
Net Income2,487.00
Cash Flow Statement (mra) ($M)
Cash From Operations1,492.00
Cash from Investing-391.00
Cash from Financing-391.00
Identifiers and Descriptors
Central Index Key (CIK)1355096

Split History

Stock splits are used by Liberty Interactive Corp. Series A QVC Group to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

17h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q2 2018 Update

2018-09-06 seekingalpha
Wallace Weitz's 13F portfolio value decreased marginally from $2.37B to $2.35B this quarter. The number of positions increased from 75 to 79. (122-1)

Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q1 2018 Update

2018-05-29 seekingalpha
Wallace Weitz's 13F portfolio value decreased marginally from $2.40B to $2.37B. The number of positions decreased from 77 to 75. (812-2)

FTD Companies: Odd Post-Earnings Decline Gives Another Shot At A High-Risk Turnaround Story

2018-05-10 seekingalpha
FTD fell 13% after Q1 earnings - despite the fact that management had already telegraphed a pretty ugly quarter. (11-1)

Charter (CHTR)/GCI Liberty (GLIBA) Update - ValueWalk

2018-04-30 valuewalk
Well, Charter Communications (CHTR) stock tanked 15% on Friday (4/27/18), and you know me, I’m a sucker for something on sale! Yup, I picked up a position in Charter at around the $252/share level and purchased a bit more GCI Liberty (GLIBA) at around $45 a share. I had originally purchased some Liberty Ventures back in January for around $57 a share (before it was spun out of Liberty Interactive and merged with GCI Communications in March), so adding at $45 was a no-brainer for me. (64-0)

FTD Companies: A Justified Relief Rally, And A High-Risk, Huge-Reward Play After That

2018-04-11 seekingalpha
Short covering no doubt is helping, but there are some ways to suggest that some value can be wrung out of a steadily shrinking equity slice. (11-1)

CUSIP: 53071M104